CRISPR Therapeutics Advances Gene-Editing Medicines with Casgevy Approval
CRISPR Therapeutics AG, a biotechnology company, is focused on developing gene-editing medicines using CRISPR/Cas9 technology. Their most advanced product, Casgevy (exa-cel), is an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. Casgevy utilizes CRISPR/Cas9 gene editing to modify a patient’s blood stem cells and has received regulatory approval in several markets for eligible patients suffering from sickle cell disease and transfusion-dependent beta thalassemia. This product marks one of the first medicines based on CRISPR gene-editing technology to achieve regulatory approval. The company, founded in 2013, operates internationally with corporate activities in Switzerland and the United States. Beyond its hemoglobinopathy program, CRISPR Therapeutics is also pursuing investigational therapies in areas such as cancer, type 1 diabetes, and immune-mediated diseases through both internal research and collaborations. The scientific foundation of the company is linked to CRISPR pi...